13F data as of 2025-03-31 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

CUSIP

81750R102

FAQ

Who are the top institutional investors holding SERES THERAPEUTICS INC (MCRB1EUR)?

Major stakeholders currently include Flagship Pioneering, LLC ($16.2M), FMR LLC ($15.3M), Vanguard Group INC ($4.3M). Based on the latest 13F filings, there are a total of 61 tracked investment funds and institutions maintaining positions in MCRB1EUR.

What is the overall institutional sentiment toward MCRB1EUR recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $12.0M, driven by 52 managers accumulating shares while 28 reduced their exposure.

Which institutions have been selling or reducing their MCRB1EUR positions?

In the latest period, 5 funds trimmed their holdings, and 23 managers completely exited their positions. The aggregate reported sell value was $76.5M.

Are there any notable investors adding MCRB1EUR to their portfolios?

Yes, buying activity remains notable. 49 institutions opened new positions in {ticker}, and 3 existing holders added to their shares. The total reported buy value for the quarter amounted to $41.7M.